Company Profile
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
Emvision expects to release trial results for its Emu stroke-detection device in November Syntara’s...
Read ArticleXi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for t...
Read ArticleIn drug development there’s a narrow window to get to market and long delays tend to be fatal – and...
Read ArticleMomentum trading involves buying a stock that has shown a significant movement in price or volume. O...
Read ArticleNews relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD f...
Read ArticleAsk any chief of a development-stage biotech about the prospect of a partnering or licencing deal an...
Read ArticleASX health sector falls in line with broader markets as macroeconomic factors continue to create vo...
Read ArticleSignificant changes for Pharmaxis (ASX:PXS) with the company announcing a new name and the s...
Read ArticleBenchmark index falls on Monday, closing out the day down 0.21% Utilities and Materials sectors ed...
Read ArticleL’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supr...
Read ArticleBenchmark slides throughout the day after a shocker on Wall Street last night. Utilities did best b...
Read ArticleThe FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergenc...
Read ArticleEarnings reports dominated headlines in August Despite solid results from ASX healthcare giants, th...
Read ArticleClinical stage drug development company Pharmaxis (ASX:PXS) has announced the publication in...
Read ArticleAustralian biotech has attracted US investments in the last five years Among ASX stocks to get fund...
Read ArticleWelcome to the FNArena Corporate Results Monitor. Today's Reports: ((AKE)) - Allkem ((ALU)) - Alti...
Read ArticleNeuren’s US FDA approval for trofinetide has seen its share price boosted ~130% in past year Eye...
Read ArticleBiotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two g...
Read ArticleThe end of pandemic and higher rates have subdued biotech market But there are signs now the sector...
Read ArticleASX health stocks fall in past five days with Power noting larger names trading on attractive valu...
Read ArticlePharmaxis (ASX:PXS) has announced details of a final interim analysis of data from ten patie...
Read ArticlePharmaxis (PXS) releases the final set of interim data from its phase two cancer trial, revealing “e...
Read ArticleLittle Green Pharma awarded commercial tender by French government Pharmaxis says its bone marrow c...
Read ArticleAn additional news report on the recommendation, valuation, forecast and opinion changes and updates...
Read ArticleBrisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “gam...
Read ArticleSmall cap health stocks are not known to pay dividends But there’s a handful of such stocks on the...
Read ArticleBiotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We...
Read ArticleThe market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts...
Read ArticleASX health stocks have fallen in the past five days in line with broader markets Volpara Health Tec...
Read ArticlePharmaxis (ASX:PXS) has announced that a phase 1c trial of its novel topical drug treatment...
Read ArticlePfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of...
Read ArticleFurther testing of a potentially breakthrough scar treatment is in the works after UWA researchers f...
Read ArticleASX sinks to -0.4% before slogging its way back to -0.22% for the day. Tech stocks were all over th...
Read ArticleThe Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health...
Read ArticleArtificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discove...
Read ArticleA handful of ASX biotechs are entering their crucial stages of development Promising outlooks for P...
Read ArticleDr Boreham’s Crucible: Radiopharm Theronostics By Tim Boreham ASX code: ((RAD)); NASDAQ code (propos...
Read ArticlePharmaxis CEO Gary Phillips said, “The agreement with the FDA to expand the patient populati...
Read ArticlePharmaxis widens clinical trial following FDA guidance Aroa receives US FDA 510K clearance Cynata g...
Read ArticleASX health stocks fall 0.9% in the past five days Healius receives a $1.52 billion takeover offer f...
Read ArticleSaturday March 11 was a typical balmy autumnal afternoon in Melbourne, but Neuren (ASX:NEU) chief Jo...
Read ArticleThe ASX 200 was up 0.39% and ASX XEC slips 0.42% 10 out of 11 sectors were higher lead by Communica...
Read ArticleThe FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have g...
Read ArticleJapanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based devic...
Read ArticleThe long and short of 2022 is that it was a frustrating period for the Australian biotech sector but...
Read ArticlePharmaxis (ASX:PXS) has announced the appointment of experienced senior global biopharmaceut...
Read ArticleWarrego Energy puts out initial substantial shareholder notice for Gina Rinehart entities following...
Read ArticleASX health stocks have been out of favour this year with rotation away from growth to value sector...
Read ArticleTom Boreham notes small caps with cash on the balance sheet are the safer bet compared to ‘pre-reven...
Read ArticlePharmaxis completes $10 million capital raise, announces positive interim results for Phase II canc...
Read ArticleWe take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks fr...
Read Article27 new biotech companies listed on the ASX the last two years Australian companies need access to U...
Read ArticleCEO Gary Phillips said, “We are confident that these results, if repeated in the whole study...
Read ArticleIt’s Tuesday afternoon, and after a long, hard day buying and selling bits of paper that say you own...
Read ArticleBlood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks...
Read ArticleASX code: ((PXS)) Share price: 8.4 cents Shares on issue: 549,139,613 Market cap: $46.1m Chief execu...
Read ArticleAs with almost every other drug developer on the planet, Vectus Biostsyems (ASX:VBS) co-founder Maur...
Read ArticleBotanix submits NDA to the US FDA Pharmaxis reports on latest clinical trials PainChek to expand to...
Read ArticleWhether it’s two-for-one shopper docket deals or snaring a slightly used treadmill from the ‘free’ c...
Read ArticleActing out your dreams could be a sign of a neurological disease, a study finds ASX-listed Pharmaxi...
Read ArticleThe ASX healthcare index has fallen this week as a strong reporting season comes to a close with ou...
Read ArticlePharmaxis gets ~$5m to collaborate on a Phase 2 study of lead drug, PXS‐4728. Imugene escalates to...
Read ArticleThe ASX will open lower on Thursday Wall Street slipped for the fourth consecutive day Europe’s inf...
Read ArticleWelcome to the FNArena Corporate Results Monitor. Today's Reports: ((BHP)) - BHP Group ((CGF)) - C...
Read ArticleWhat are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up...
Read ArticleUS FDA approves the first clinical trial using naturally derived psychedelic drugs It could open po...
Read ArticleA recent research reveals which biotech segments VCs are ploughing billions of dollars into We list...
Read ArticleThe Healthcare sector has been struggling as the pandemic wanes But most money managers are still b...
Read ArticleShareCafePXS – Morgans rates the stock as Speculative Buy Morgans initiates coverage of commercial s...
Read ArticleThe healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak mark...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleBiotech sector has had a tough time recently But there are signs of things improving this year A lo...
Read ArticleTelehealth was already a growing space even before the pandemic, but COVID had launched it into the...
Read ArticleThe ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial t...
Read ArticleAustralian company Pharmaxis (ASX:PXS) has announced that a phase 1c trial of its novel topi...
Read ArticleThe collaboration with the research team led by Professor Fiona Wood AM has dosed the first patients...
Read ArticlePharmaxis (ASX:PXS) says it welcomes new drug development grants from the federal government...
Read Article“Together, our work aims to support commercialisation of new treatment approaches for pancreatic can...
Read ArticlePharmaxis (PXS) receives drug development grants from the Australian government, funding two resear...
Read ArticleUS stocks fell hard as Fed outlines rate cut plan There were more investor jitters over interest rat...
Read ArticleAt the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, be...
Read ArticleIt’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and...
Read ArticleThe life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, th...
Read ArticlePharmaxis (PXS) has announced its oversubscribed share purchase plan (SPP) has raised $2.6 million...
Read ArticleThe clinical-stage drug development company opted to increase its raise target from A$2 million afte...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 los...
Read ArticleAmong a range of factors for the outperform recommendation, Taylor Collison cites the company’s two...
Read ArticleWelcome to the Market Herald Deal Room for this Friday, where we review the week in capital raising....
Read ArticleThe capital raise is part of its move to bolster its balance sheet as it enters a transformational 1...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 los...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleAmplia targets human trials for pancreatic cancer drug Noxopharm subsidiary enters licence agreemen...
Read Article“Pharmaxis is entering a transformational 12 months with two clinical studies expected to deliver sa...
Read ArticleThe hot debut of Evolution Energy Minerals (ASX:EV1) was not enough to save the ASX resources sector...
Read ArticleThe ASX posted steady gains to start the week on Monday, with investors preferences leaning towards...
Read ArticlePharmaxis is tapping investors to raise $9.2 million, with the capital set to support the next phase...
Read ArticleIND approved to trial PXS-5505 added to current standard of care in newly diagnosed unresectable hep...
Read ArticleThe ASX closed down again today in spite of resources and tech gaining over 1%. The ASX 200 fell 0.2...
Read Article“The rapid progression from the compelling pre-clinical work presented for the first time in August...
Read ArticleThe ASX 200 Health Index (XHJ) is up by 0.57% at the time of writing, compared to the broader index...
Read ArticleThe US FDA has cleared Pharmaxis' (ASX:PXS) Investigational New Drug (IND) application for a...
Read Article“Pharmaxis is entering a potentially transformational period as it advances a portfolio of novel sma...
Read ArticleClinical stage drug development company Pharmaxis (ASX:PXS) has commenced dosing in the phas...
Read ArticleBone marrow cancer affects one in 100,000 people, but Pharmaxis’ lead asset could one day help treat...
Read ArticleThe ASX 200 was unable to break free from its recent shackles, edging lower by 0.11% in the Wednesda...
Read Article“We are very pleased to have completed the dose-escalation phase of this study with such clear and p...
Read ArticleThe ASX 200 health stocks index (XHJ) is falling by 0.55% at the time of writing, compared to the br...
Read ArticlePharmaxis (ASX:PXS) has announced further positive results of data analysis from a phase 1c...
Read ArticleAlthough earnings results were the main theme in August, there were also some notable healthcare bre...
Read ArticleTopical treatment safe and well tolerated in study of healthy volunteers Full inhibition of lysyl...
Read Article“We will be investigating the safety of 3 months’ treatment with PXS‐6302, and exploring if 3 months...
Read ArticleTop of the ASX health stocks today is Creso Pharma (ASX:CPH), which rose more than 10% after announc...
Read ArticlePharmaxis (ASX:PXS) has announced that its novel topical drug treatment for scarring has del...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 7...
Read ArticlePharmaxis will receive an upfront US$250,000 payment for the 12‐month option and a further US$2.5 mi...
Read ArticleHighlights AVITA Medical disclosed that the US Food and Drug Administration (FDA) has authorised...
Read ArticleGlobal markets stay cool US stocks edged higher overnight to post their fifth straight day of gains...
Read ArticleSummary Latitude Group Holdings has cracked a deal for fintech Symple to accelerate business gr...
Read ArticleDATA PRESENTED FROM COLLABORATION OF PHARMAXIS AND UNIVERSITY OF ROCHESTER MEDICAL CENTER AT US SCIE...
Read ArticleThe S&P/ASX200 closed up Thursday, gaining 7.90 points or 0.11% to 7,511.10 and setting a new 10...
Read ArticleSummary Benchmark index, the ASX200, rose 0.1% to hit a fresh closing high of 7,511. Eight of t...
Read ArticleSummary Emyria has signed a deal with the University of Western Australia (UWA) to develop a nov...
Read ArticleASX 200 health stocks index (XHJ) rose by 0.23% this morning, compared to the broader index which ro...
Read ArticleA research team at the University of Rochester Medical Center in New York State has been investigati...
Read ArticlePharmaxis (ASX:PXS) has announced the first public presentation of data from a preclinical s...
Read ArticleWall Street mixed on Fed’s statement US stock markets were mixed overnight, after the US Fed Vice Ch...
Read ArticleThe ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the...
Read ArticleSummary REA Group (ASX:REA) completes transaction with PropertyGuru BNK Banking (ASX:BBC) annou...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 7...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleIt wasn’t a happy start to the new financial year for Australia’s bourse, which lost nearly two thir...
Read ArticleUnder the agreement, BTC Health will acquire marketing authorisations for both products in Australia...
Read ArticleAustralian company Pharmaxis (ASX:PXS) has announced results of data analysis from the first...
Read ArticleThe second dose cohort of the clinical trial is fully recruited and dosing of all patients has comme...
Read ArticleSummary The OVT share price has risen by 50% to AU$0.003 in today’s session, clocking a volume o...
Read ArticleThe company’s PXS-5505 multinational trial in Myelofibrosis has been cleared by the safety committee...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has ret...
Read ArticleA drug candidate discovered by the Australian company Pharmaxis (ASX:PXS) will be the focus...
Read ArticleSummary Pharmaxis Ltd and Charlie Teo Foundation have identified a new drug that shows promise i...
Read ArticlePXS-5505 will enter pre-clinical efficacy testing for glioblastoma, the most common form of brain ca...
Read ArticleThe capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the fir...
Read ArticleSummary Digital health behemoth ResMed has released its quarterly results for the March 2021 qua...
Read ArticleInflammatory diseases company Pharmaxis (ASX:PSX) this month welcomed a familiar biotech name to the...
Read ArticleThe clinical stage drug development company has boosted its balance sheet with a $4.4 million placem...
Read ArticleIf you want to know which ASX stocks fund managers and famous investors are putting their money into...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleAustralian company Pharmaxis has sold Russian distribution rights to cystic fibrosis therapy...
Read ArticleSource: Monster Ztudio, Shutterstock Summary Pharmaxis’ shares rose on the sale of Russian dist...
Read ArticleAfter a few near misses, the ASX has punched through 7,000 percentage points for the first time sinc...
Read ArticleThe company has also strengthened its balance sheet with the sale of Bronchitol Russian distribution...
Read ArticleSource: Jirapong Manustrong, Shutterstock The ASX 200 is trading in the positive territory today. T...
Read ArticleShareCafeAustralia…1 hour in… ASX200 up 18 ASX200 up 18 points (0.3%) to 6994 Brainchip (+18%); b...
Read ArticleToday, the ASX finished slightly in the green, tech stocks were up over 2 per cent, and another IPO...
Read ArticleShareCafeAustralia…1 hour in… ASX200 up 15 ASX200 up 15 points (0.2%) to 6989 A2Milk (+3%); upgra...
Read ArticlePharmaxis (ASX:PSX) has announced a partnership to launch a world-first clinical trial that...
Read ArticleRisk on sentiment has returned to the ASX. The ASX finished 0.78 per cent higher at 6,791 points alt...
Read ArticleThe trial will investigate the potential of PXS‐6302 treatment to transform trauma recovery by block...
Read ArticlePharmaxis (ASX:PXS) has announced that its US partner Chiesi has launched BRONCHITOL (mannit...
Read ArticleUS stocks dip as Treasury yields spike US stocks dipped from record highs on Thursday trading in the...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks f...
Read ArticleAustralian pharmaceutical company Pharmaxis (ASX:PXS) has enrolled the first patient in a cl...
Read ArticleSummary ASX-listed Pharmaxis has enrolled the first patient for the clinical trial to evaluate a...
Read Article“Its potential to modify the course of the disease by directly targeting bone marrow fibrosis will m...
Read ArticleSummary Australian pharmaceutical research player Pharmaxis has shipped the first batch of Bronc...
Read Article“This represents a proud and very rare achievement for a home‐grown pharmaceutical research company,...
Read ArticlePharmaxis (ASX:PXS) has triggered a US$3 million milestone payment after exporting the first...
Read ArticlePharmaxis (ASX:PXS) has received a US$7 million milestone payment from its US licensee Chies...
Read ArticleSummary Pharmaxis Ltd (ASX:PXS) has received a US$7 million milestone payment from Chiesi. The...
Read ArticlePharmaxis is now advancing clinical development of a new cancer drug.
Read ArticleThe Pharmaxis Ltd (ASX: PXS) share price is up today on the news it has received a substantial paym...
Read ArticleSummary Leading medical imaging company Pro Medicus Limited has signed a five-year deal with Med...
Read ArticleIt is indeed possible to get something from nothing. Four small-caps appear to be defying the norms...
Read ArticleThe company expects to announce receipt of milestone payments and the start of sales from its Bronch...
Read ArticlePresenting companies were Cynata Therapeutics Ltd, Recce Pharmaceuticals Ltd and Pharmaxis Ltd (ASX:...
Read ArticlePharmaxis has become one of the small number of local life science companies to secure FDA a...
Read ArticleShareCafeBhronchitol FDA Approval Transformative for Pharmaxis Pharmaceutical research company Pharm...
Read ArticlePharmaxis Ltd (ASX: PXS) today published a quarterly update in which the company reported three sig...
Read ArticleShareCafeAustralia…One Hour In…ASX Up 6 Points ASX200 up 6 points (0.1%) to 5933. – AMP (+8.6%); say...
Read ArticleAustralian drug discovery will now be available for cystic fibrosis patients in the USA in a “transf...
Read ArticleIn what has been described as a “transformational step” Pharmaxis (ASX: PXS) has collared United Sta...
Read ArticleThe company is focused on the phase 1/2 clinical trial of its pan-LOX inhibitor PXS-505 in myelofibr...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleA quick wrap of the ASX’s key winners and losers on Monday, September 7. Data is taken after the mar...
Read ArticlePharmaxis (ASX:PXS) and Biotron (ASX:BIT) have gone in polar opposite directions in 2020 and today t...
Read ArticleShareCafeAustralia…1 Hour In…ASX Up 12 Points ASX200 up 12 points (0.2%) to 5937. – Afterpay (-3.5%)...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleThe Australian Government matched funding under the Biomedical Translation Bridge program will allow...
Read ArticleA quick wrap of the ASX’s key winners and losers on Thursday, August 20. Data is taken after the mar...
Read ArticleSydney-based Pharmaxis (ASX:PXS) says the US FDA has completed a safety review of the compan...
Read ArticleThe Food and Drug Administration has completed a safety review of the company’s Investigational New...
Read ArticleA timeline agreed with US licensee Chiesi Farmaceutici will see the US$7 million payment made upon U...
Read ArticleThe Pharmaxis Ltd (ASX: PXS) share price has surged 8.24% today at the time of writing, after the p...
Read ArticleThe application to the US Food and Drug Administration (FDA) is for a planned phase 1/2 study of PXS...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleSydney-based biopharmaceutical company Pharmaxis (ASX:PXS) has announced the US FDA has gran...
Read ArticleOrphan designation qualifies the sponsor of the drug for various development incentives such as redu...
Read ArticleResubmission follows Chiesi Group’s successful completion of a supplemental human factor study which...
Read ArticleSydney-based biopharmaceutical company Pharmaxis has announced the appointment of experience...
Read ArticleThe new US-based non-executive director is an experienced senior global pharma and biotech executive...
Read ArticleThe company completed both its phase 1b trial of its systemic pan‐LOX inhibitor and a further phase...
Read ArticleA pre-clinical program, regulatory advice and opinion from leading clinicians supports progression i...
Read ArticleCancer hopeful Pharmaxis (ASX: PXS) is moving ahead with a treatment for a rare bone cancer called m...
Read ArticleAustralian company Pharmaxis (ASX:PXS) says positive results from phase 1b and long-term tox...
Read ArticleThe company is adding to the LOXL2 data package with a small but important phase 1 study investigati...
Read ArticleShares overcame an early wobble to resume their push towards all-time highs. The ASX 200 dipped...
Read ArticlePharmaxis’ (PXS) German partner has dumped its nonalcoholic steatohepatitis drug The company bough...
Read ArticleBoehringer Ingelheim diabetic eye study continues after discontinuation of NASH trial.
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticlePharmaxis shares are in free-fall in pre-open trading, after a German pharmaceutical giant declined...
Read ArticleWhether a day trader or a long-term investor, we often examine research released by industry experts...
Read ArticlePharmaxis (ASX:PXS) has some big news from its German partner, but won’t yet say whether it’s good o...
Read ArticleAir pollution is a growing problem that in recent days has reached our own backyard. Because of the...
Read ArticleAs the year winds down and AGM season concludes brokers have been busy filling their Christmas stock...
Read ArticleNo other sector among ASX small caps has had a better year than the health sector. On average small...
Read ArticleStockhead’s resident Health and Biotech expert Tim Boreham is coming to you live from the 2019 AusB...
Read ArticleDrug Development Process The drug development process starts from drug discovery and ends at the lau...
Read ArticleThere are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so...
Read Article"We are currently pursuing a number of different partnering options to enable this drug to c...
Read ArticleThe company’s CEO Gary Phillips has presented during the 2019 AusBiotech Conference in Melbourne.
Read ArticleSydney-based Pharmaxis (ASX:PXS) has provided an update on the FDA's consideration of its cy...
Read ArticleThe FDA review of the Bronchitol NDA (new drug application) is expected to be completed in the secon...
Read ArticleThis drug is targeting the treatment of cancers including myelofibrosis and pancreatic cancer.
Read ArticleHealth stocks are reckoned amid those that can rapidly grow from a single line of product with small...
Read ArticleThe Board of advanced Australian lithium developer Core Lithium (ASX: CXO) has announced the appoint...
Read ArticleReceipt of this incentive adds to the company’s cash funds, which were $31 million at 30 June 2019.
Read Article“The R&D tax incentive provides significant leverage to the Pharmaxis research team’s de...
Read ArticlePharmaxis was ranked 38 out of the 100 companies named as innovators in the small to medium- sized e...
Read ArticlePharmaxis, one of last year’s biggest small cap reporting season winners, has tumbled 412 per cent i...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and the worst) performing ASX small caps in morning tr...
Read ArticleOn Stockhead today, what small fries can learn from big health caps, an expert’s view of where crypt...
Read ArticleThe company is confident that the FDA will have the information it requires to be able to approve Br...
Read ArticlePharmaxis (ASX:PXS) chief Gary Phillips is keen to differentiate the drug developer from his local p...
Read ArticleI have recently spent some time reviewing the annual reports and announcements from S&P/ASX 200...
Read ArticleIn this week's Weekly Insights (published in two parts):-Crucial Question: Is It 1995 or 2007?-Convi...
Read ArticleAvita Medical Ltd Strong Performance During the Third Quarter of 2019: Avita Medical Ltd (ASX: AVH)...
Read ArticleIf Bronchitol is approved by the US FDA, Pharmaxis will receive US$10 million.
Read ArticleOpen an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.